otc 23%
mcassab comÉrcio e indÚstria ltda. - oxitetraciclina; - antimicrobianos gerais; antifÚngicos e antiprotozoÁrios (coccidios, flagelados)
ruxience
pfizer brasil ltda - rituximabe - antineoplasicos citotoxicos
mhyosphere pcv id
laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - porcos - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.
circomax myco
zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - imunológicos para suidae - suínos (para engorda) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection. onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination. duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination. in addition, vaccination has been shown to reduce body weight gain losses under field conditions.
padcev
astellas pharma europe b.v. - enfortumab vedotin - carcinoma, transitional cell; urologic neoplasms - agentes antineoplásicos - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.
diclofenac pharmakern 20 mg/g gel
pharmakern portugal - produtos farmacêuticos, sociedade unipessoal, lda. - diclofenac - gel - 20 mg/g - diclofenac, dietilamónio 23.2 mg/g - diclofenac - n/a - duração do tratamento: curta ou média duração
topiramato aurovitas 25 mg comprimido revestido por película
generis farmacêutica, s.a. - topiramato - comprimido revestido por película - 25 mg - topiramato 25 mg - topiramate - genérico - duração do tratamento: longa duração
topiramato aurovitas 200 mg comprimido revestido por película
generis farmacêutica, s.a. - topiramato - comprimido revestido por película - 200 mg - topiramato 200 mg - topiramate - genérico - duração do tratamento: longa duração
voltaren emulgelex 20 mg/g
haleon portugal, lda. - diclofenac - gel - 20 mg/g - diclofenac, dietilamónio 23.2 mg/g - diclofenac - n/a - duração do tratamento: curta ou média duração
voltaren emulgelex 20 mg/g
haleon portugal, lda. - diclofenac - gel - 20 mg/g - diclofenac, dietilamónio 23.2 mg/g - diclofenac - n/a - duração do tratamento: curta ou média duração